Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 10,649 |
|
|||||
| News | - | ||||||
| Day High | 7.9964 | Low High |
|||||
| Day Low | 6.75 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Titan Pharmaceuticals Inc | TTNP | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.12 | 1.72% | 7.09 | 15:00:41 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 7.02 | 6.75 | 7.9964 | 7.09 | 6.97 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 146 | 10,649 | US$ 7.27 | US$ 77,379 | - | 5.00 - 16.60 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 17:05:31 | 1 | US$ 6.77 | USD |
Titan Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 5.54M | 781.50k | - | 184k | -5.57M | -7.13 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Titan Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/25/2024 | 15:33 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/25/2024 | 15:29 | GlobeNewswire Inc. | Titan Pharmaceuticals Fully Compliant With NASDAQ Listing.. |
| 1/18/2024 | 15:59 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/08/2024 | 16:13 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/28/2023 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/28/2023 | 15:15 | GlobeNewswire Inc. | Titan Pharmaceuticals Announces Reverse Stock Split and.. |
| 11/28/2023 | 15:47 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
| 11/17/2023 | 15:03 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements |
| 11/15/2023 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/26/2023 | 15:33 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 10/26/2023 | 15:31 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 10/26/2023 | 15:29 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TTNP Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.21 | 7.9964 | 6.75 | 7.11 | 1,554 | -0.12 | -1.66% |
| 1 Month | 7.11 | 9.07 | 6.61 | 7.14 | 5,389 | -0.02 | -0.28% |
| 3 Months | 6.09 | 9.29 | 5.49 | 7.41 | 8,749 | 1.00 | 16.42% |
| 6 Months | 8.29 | 10.00 | 5.00 | 7.23 | 25,467 | -1.20 | -14.48% |
| 1 Year | 15.60 | 16.60 | 5.00 | 10.04 | 43,458 | -8.51 | -54.55% |
| 3 Years | 50.00 | 62.00 | 5.00 | 22.37 | 155,094 | -42.91 | -85.82% |
| 5 Years | 1,080.00 | 1,308.00 | 5.00 | 135.88 | 4,145,368 | -1,072.91 | -99.34% |
Titan Pharmaceuticals Description
| Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine. |
